In their study, SGLT2 inhibitors showed a higher prevalence of mild to moderate depression (p<0.001; OR: 1.74) and cognitive impairment (p=0.039, OR: 1.32) compared to controls [17]. This evidence concerns the gene SLC5A2 and depressive symptom measurement.